PedAM
Pediatric Disease Annotations & Medicines
| Disease | vascular disease |
| Phenotype | C0011860|type 2 diabetes |
| Sentences | 223 |
| PubMedID- 20804517 | Aims: to analyse the association between glycosylated haemoglobin a1c (hba1c) and cardiovascular disease (cvd) in patients with type 2 diabetes in the swedish national diabetes register (ndr). |
| PubMedID- 26056618 | Accordingly, we constructed a predictive model for the appearance of cardiovascular diseases in patients with type 2 diabetes admitted via the emergency department. |
| PubMedID- 20847892 | Evidence suggests that the maintenance of a large muscle mass may reduce metabolic risk factors—namely, obesity, dyslipidaemia, and type 2 diabetes mellitus—associated with cardiovascular disease [13–15]. |
| PubMedID- 23718574 | Cardiovascular diseases in patients with type 2 diabetes are a large and increasing health problem. |
| PubMedID- 24101925 | It has been reported that metabolic syndrome and insulin resistance are the major components of atherosclerosis risk in patients with diabetes and also in individuals without diabetes with insulin resistance [3, 20, 21], whereas the role of hyperglycemia in cardiovascular disease associated with type 2 diabetes is less clear [22]. |
| PubMedID- 24567354 | Increased white blood cell (wbc) count is related to cardiovascular disease in patients with type 2 diabetes mellitus; raised neutrophil lymphocyte ratio (nlr) is associated with metabolic syndrome. |
| PubMedID- 25657589 | This review will discuss cardiovascular disease in type 2 diabetes, the effects of glycemic control and insulin therapy on cardiovascular disease, and focus specifically on the cardiovascular effects of glargine insulin. |
| PubMedID- 20103560 | Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the kelly west award lecture 2008. |
| PubMedID- 22108456 | However, the underlying mechanisms linking type 2 diabetes with cardiovascular disease remain poorly understood. |
| PubMedID- 20467927 | Results of recent large-scale intervention trials, such as accord, advance, and vadt, seem to undermine the concept that tight glycemic control confers some protection against cardiovascular disease in patients with type 2 diabetes, while maintenance of near-normal glycemic control from earlier stage of the disease and during acute coronary events seems to be more beneficial. |
| PubMedID- 20647285 | Objective: to determine the extent to which intensive dietary intervention can influence glycaemic control and risk factors for cardiovascular disease in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment. |
| PubMedID- 20048277 | Concerns about meta-analysis of glucose control and cardiovascular disease in type 2 diabetes. |
| PubMedID- 23810406 | Conclusion: achieving adequate control of risk factors for cardiovascular disease in patients with type 2 diabetes remains a clinical challenge. |
| PubMedID- 25905182 | However, intensive glycemic control does not have a major impact in reducing cardiovascular disease in patients with type 2 diabetes. |
| PubMedID- 22632266 | Mitochondrial oxidative stress is a major etiological factor in the development of cardiovascular disease associated with type 2 diabetes. |
| PubMedID- 23675676 | Aims: there is limited evidence regarding the association between physical activity and vascular complications, particularly microvascular disease, in patients with type 2 diabetes. |
| PubMedID- 23526157 | There is a growing evidence linking microvascular complications with cerebrovascular and cardiovascular disease in patients with type 2 diabetes. |
| PubMedID- 24804267 | There is a relationship between adma and macrovascular disease in type 2 diabetes, but further studies are needed to understand whether increased adma levels are a cause of macrovascular disease or a result of macrovascular disease. |
| PubMedID- 26246459 | Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the american heart association and the american diabetes association. |
| PubMedID- 25466521 | The differences between relative risks of different cardiovascular diseases in patients with type 2 diabetes have implications for clinical risk assessment and trial design. |
| PubMedID- 20601395 | Methods and results: one hundred and fifty type 2 diabetes patients with cardiovascular disease (cvd) or >/= 1 other cvd risk factor were randomized to receive rosiglitazone vs. |
| PubMedID- 21867459 | Comprehensive search terms were devised to identify articles describing micro- and macrovascular complications including nephropathy, neuropathy, retinopathy, and cardiovascular disease associated with type 2 diabetes. |
| PubMedID- 21617108 | Although meta-analyses have suggested that intensive glycemic control reduces cardiovascular disease in individuals with type 2 diabetes (47,48), clinical trials have not consistently demonstrated a reduction in macrovascular disease (myocardial infarction or stroke) with intensive therapy aimed at lowering glucose concentrations in type 2 diabetes. |
| PubMedID- 20934769 | Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus. |
| PubMedID- 24498934 | Ev-markers and the risk of new onset type 2 diabetes in patients with manifest cardiovascular disease. |
| PubMedID- 24073334 | It increases the severity of ischemic vascular diseases and, with obesity and type 2 diabetes, is one of the important risk factors for chronic kidney disease (ckd). |
| PubMedID- 25849783 | Background: both non-alcoholic fatty liver disease (nafld) and type 2 diabetes increase the risk of developing cardiovascular disease. |
| PubMedID- 23937815 | Moreover we must remember that an early and intensive treatment of dyslipidemia and hypertension is essential for the prevention of cardiovascular disease in patients with type 2 diabetes. |
| PubMedID- 24920930 | Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. |
| PubMedID- 22905215 | 7,447 participants (55–80 years, 57% women) free of cardiovascular disease, but with either type 2 diabetes or ≥3 cardiovascular risk factors. |
| PubMedID- 23540820 | Screening for peripheral vascular disease in patients with type 2 diabetes in malta in a primary care setting. |
| PubMedID- 25251664 | Patient empowerment programme in primary care reduced all-cause mortality and cardiovascular diseases in patients with type 2 diabetes mellitus: a population-based propensity-matched cohort study. |
| PubMedID- 23522916 | Aim: to explore risk factors for peripheral arterial disease (pad) as well as the association between toe blood pressure and subclinical and clinical central vascular disease in patients with type 2 diabetes. |
| PubMedID- 21749443 | Waist circumference and metabolic risk factors have separate and additive effects on the risk of future type 2 diabetes in patients with vascular diseases. |
| PubMedID- 22569118 | Background: although most deaths among patients with type 2 diabetes (t2d) are attributable to cardiovascular disease, modifiable cardiovascular risk factors appear to be inadequately treated in medical practice. |
| PubMedID- 20860758 | Although data suggest that the control of hyperglycaemia may have a different impact on primary and secondary prevention of cardiovascular disease in patients with type 2 diabetes, in the navigator study, patients in these two groups were pooled and evaluated together (38). |
| PubMedID- 24506465 | Background: endothelial dysfunction is an early event of cardiovascular disease in type 2 diabetes (t2d) and can occur before albuminuria. |
| PubMedID- 23238663 | Dietary interventions that could reduce the risk of development of cardiovascular disease (cvd) in patients with type 2 diabetes mellitus (t2dm) would clearly be advantageous instead of expensive pharmacological treatments. |
| PubMedID- 25227555 | Impact of chronic kidney disease on the prevalence of cardiovascular disease in patients with type 2 diabetes in spain: percedime2 study. |
| PubMedID- 20305745 | Il-6 is a well-known risk marker of cardiovascular disease associated with obesity, type 2 diabetes and myocardial infarction. |
| PubMedID- 24779961 | Moreover, circulating levels of tnfr2 predict morbidities such as cardiovascular disease and nephropathy in patients with type 2 diabetes (14,15). |
| PubMedID- 23466074 | Role of relationship between hba1c, fibrinogen and hdl-cholesterol on cardiovascular disease in patients with type 2 diabetes mellitus. |
| PubMedID- 21447669 | As the results of the heart2d trial suggest that glucose variability is not a risk factor for cardiovascular diseases in patients with type 2 diabetes treated with insulin (1,2), several “burning” questions can be raised, why could glucose variability be a risk factor for cardiovascular diseases in patients with type 2 diabetes who are treated with oral hypoglycemic agents alone, but not in those who are treated with insulin, and does insulin per se neutralize the deleterious effects of glycemic variability on oxidative stress in patients treated with it? |
| PubMedID- 20580779 | Our results suggested that incorporation of almonds into a healthy diet has beneficial effects on adiposity, glycemic control, and the lipid profile, thereby potentially decreasing the risk for cardiovascular disease in patients with type 2 diabetes mellitus. |
| PubMedID- 23230099 | The reduced incidence of subclinical outcomes in the intensive group indicates that these interventions reduced the incidence of macroangiopathy, which suggests that this intensified, multifactorial intervention can produce a marked effect on the primary prevention of macrovascular disease in patients with type 2 diabetes. |
| PubMedID- 22184101 | Study selection: a study was eligible when it described the development, validation or impact assessment of a model that was constructed to predict the occurrence of cardiovascular disease in people with type 2 diabetes, or when the model was designed for use in the general population but included diabetes as a predictor. |
| PubMedID- 20798334 | Objective: cerebral microvascular disease associated with type 2 diabetes may exacerbate the effects of aging on cognitive function. |
| PubMedID- 20368470 | Objective: to examine retinal vascular caliber, an indicator of early microvascular disease and depression in patients with type 2 diabetes. |
| PubMedID- 22164268 | Although observational studies have reported a strong association between hyperglycemia and increased risk for cardiovascular disease in individuals with type 2 diabetes, the results of recent interventional randomized controlled trials in establishing the benefit of intensive glycemic control on cardiovascular outcomes have been elusive [19]–[22]. |
| PubMedID- 25212259 | Development of a prediction model for fatal and non-fatal coronary heart disease and cardiovascular disease in patients with newly diagnosed type 2 diabetes mellitus: the basque country prospective complications and mortality study risk engine (bascore). |